CeeDee Lamb takes big hit from sprinting official while WR is in street clothes on the sideline ...

Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high ...

Investing.com -- FibroGen Inc (NASDAQ: FGEN) stock jumped 9.9% following positive feedback from the U.S. Food and Drug Administration supporting the advancement of roxadustat for treating anemia in ...

FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic ...

HDFN is a common cause of fetal anemia in infants, and it can lead to serious complications if not treated early.

Technological advances and new tools may offer the best chance to help underdeveloped blood deserts in the short term.

Download Free Sample of This Strategic Report with Industry Analysis @ The Saudi Arabia Blood Banking Market holds significant importance within the healthcare landscape of the country. Blood banking ...

The artificial blood cells market is an emerging and transformative segment in the biomedical industry, aimed at addressing the limitations of traditional blood transfusion methods.

Blood may be free in public hospitals, but low supplies leave Zimbabweans borrowing money to pay for private stocks.

It will also be available should the donors be in a situation where they themselves need a blood transfusion. NHS on the lookout for donors with rare blood types as tens of thousands tested ...

The NHS is searching for blood donors with rare blood types so it can ensure patients in need can receive “precision-matched” blood.